Dr. Xiaoqiang Kang, Founder, Chairman, and CEO of Leads Biolabs, said: "Focusing on the prevailing unmet clinical needs and core challenges in immuno-oncology (IO), Leads Biolabs has established a differentiated layout by deeply integrating three frontier technologies: IO 2.0, TCE, and ADC. We have constructed a clinical pipeline matrix characterized by multi-mechanism fusion. By adhering to a phased development strategy encompassing single-agent validation, platform iteration, and combination expansion, we aim to systematically surmount clinical barriers such as 'cold tumors', immune resistance, and poor response. The year 2027 is poised to witness the launch of the Company's first commercial product, marking its official transition into the inaugural year of commercialization. Propelled by our robust technology platforms, we aim to advance 20+ novel molecules into clinical trials, progress 4 to 8 assets into late-stage development, and achieve commercialization for 3 products by 2030. These milestones will drive us steadily toward our ultimate vision: 'Transforming cancer into a manageable chronic disease'."

Clinical Breakthroughs & Value Realization: From Clinical-Stage Biotech to Integrated Biopharma

Since its inception, Leads Biolabs has remained committed to an "asymmetric competition" strategy, taking unaddressed clinical gaps left by PD-(L)1 inhibitors as its strategic cornerstone. By proactively anchoring its research in IO 2.0, the Company has pioneered the synergistic mechanism of "immune checkpoint inhibition plus co-stimulatory signal activation". This approach has successfully propelled LBL-024—a potential global first-in-class (FIC) PD-L1/4-1BB bispecific antibody—to the BLA (Biologics License Application) submission stage.

LBL-024: A Potential IO 2.0 Pan-Tumor Backbone Therapy with Survival Benefit. Utilizing the unique 2:2 molecular structure design of the X-body platform, LBL-024 releases PD-L1-mediated immunosuppression while conditionally activating the 4-1BB co-stimulatory pathway, achieving the synergistic effect of "releasing the brakes and stepping on the accelerator". Clinical studies have confirmed that LBL-024 not only overcomes the global technical challenge of the 4-1BB target, where no drugs have been marketed due to uncontrollable hepatotoxicity, but also demonstrates breakthrough efficacy across multiple cancer types and "cold tumors":

• Safety: With over 600 patients enrolled, liver enzyme abnormalities in LBL-024 monotherapy or combination with chemotherapy occurred only in the early stages. No cumulative hepatotoxicity was observed with long-term treatment, and the overall safety profile is similar to that of PD-(L)1 monoclonal antibodies. Dose escalation up to 25.0 mg/kg did not reach the maximum tolerated dose (MTD), and no dose-limiting toxicities (DLTs) were observed.
• Pan-cancer Efficacy: LBL-024 has demonstrated global first- or best-in-class potential in registrational or Phase II clinical studies for extrapulmonary neuroendocrine carcinoma (EP-NEC), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and biliary tract cancer (BTC).
• Cold Tumor Efficacy: LBL-024 is poised to become the first approved drug for EP-NEC, a typical cold tumor. In first-line SCLC combined with chemotherapy, the objective response rate (ORR) reached 88.1%, significantly superior to the approximately 60% of standard of care (SoC). It is also effective in PD-L1 low-expression NSCLC, achieving an efficacy breakthrough in populations difficult to cover with PD-1 monoclonal antibodies.
• Durable Response: In late-line EP-NEC, the median overall survival (mOS) reached 11.9 months, doubling that of existing regimens. A clear survival benefit trend was also observed in first-line patients, offering the potential for long-term functional cure.

LBL-024 adopts a clear and progressive development strategy: advancing from late-line to first-line, from monotherapy to combination therapy, and from orphan diseases to major indications. Currently, LBL-024 covers 13 solid tumor indications, with one pivotal registrational study and eight proof-of-concept (PoC) studies underway.

LBL-024 is set to reach a series of intensive milestones in the second half of 2026. Regarding data readouts, data from a large patient cohort for first-line NSCLC will be presented at the World Conference on Lung Cancer (WCLC) in September. In October, the European Society for Medical Oncology (ESMO) Annual Meeting will feature the pivotal single-arm registrational clinical trial data for late-line EP-NEC, alongside the latest clinical results for first-line EP-NEC, SCLC, and BTC. On the commercialization front, LBL-024 has garnered Breakthrough Therapy Designation (BTD) from the CDE, as well as Fast Track Designation (FTD) and Orphan Drug Designation (ODD) from the U.S. FDA, and ODD from the European Union. The Company expects to submit the BLA for LBL-024 to the CDE in Q3 2026. The approval of LBL-024 will signify a pivotal milestone in the Company's transition from a clinical-stage Biotech to an integrated Biopharma.

Platform-Driven, Innovation from the Source: An In-house R&D System Integrating High-Efficiency Multi-functional Platforms and Technical Capabilities

The future of oncology treatment lies in synergy, with combinations such as IO + ADC and TCE + ADC emerging as essential expansion pathways under this prevailing trend. Leads Biolabs is dedicated to expanding the reach of immunotherapy through the deep integration of its platforms. Currently, the Company has established four core technology platforms:

• X-body (4-1BB Engager) Platform (IO 2.0): This platform utilizes advanced antibody engineering to create differentiated bispecific antibodies with a 2:2 molecular architecture, successfully addressing the hepatotoxicity and narrow therapeutic window typically associated with 4-1BB agonists.
• LeadsBody (CD3 T-cell Engager) Platform (TCE): Designed to enhance efficacy and overcome treatment resistance, the next-generation LeadsBody platform has been clinically validated in hematologic malignancies by the potential best-in-class (BIC) LBL-034 (GPRC5D/CD3 bispecific antibody). For solid tumors, the platform is advancing in three strategic directions: multi-TAA (Tumor-Associated Antigen) targeting, co-stimulatory trispecific TCE, and TCE-ADC.
• TOPiKinectics Platform in the ADC Field: The differentiated TOPiKinectics platform possesses full-chain, in-house design capabilities, including payload release within the tumor microenvironment (TME). It enables targeted tumor killing while minimizing off-target toxicity, thereby resolving industry pain points such as the narrow therapeutic window and frequent resistance associated with traditional ADC treatments. Furthermore, it offers advantages such as synergistic anti-tumor effects between ADC and IO.
• World-First TDC Platform ImBiTDC™ (TCE-ADC): Leveraging proprietary antibody platforms and the TOPiKinectics platform, this technology deeply integrates TCE modules targeting tumor-specific antigens with ADC technology. This pioneers a completely new therapeutic track designed to address challenges such as overlapping toxicities and patient compliance issues associated with separate administration in traditional combination regimens. The TDC platform offers two key advantages: broad-spectrum efficacy and optimized safety. Unconstrained by the single mechanisms of either ADC or TCE, it is adaptable to diverse tumor scenarios with varying T-cell infiltration levels, T-cell functional states, and antigen expression abundance. It can efficiently kill high-antigen, high-payload-sensitive tumors, while also covering low-antigen, immunosuppressive patient populations through bystander effects and T-cell redirection. This significantly expands the eligible patient population and substantially reduces the risk of CRS, enhancing efficacy while simultaneously improving safety.

Through the progressive synergy of its technology platforms and the deep integration of multiple mechanisms, Leads Biolabs is constructing an innovative R&D ecosystem characterized by the cross-empowerment of multiple targets, molecule types, and technological routes. This ecosystem aims to lead the next generation of immuno-oncology, ensuring more cancer patients benefit from the continuous evolution of immunotherapy.

High-Speed Rail Gets a 5G-A Upgrade

GSMA, China Mobile, and Huawei jointly unveiled the 5G-A High-Speed Railway Network Acceleration Service, redefining mobile connectivity services for railway passengers. Scheduled for commercial launch in China in August 2026, the package is built on a "1+3+5" framework:

One exclusive identity: A dynamic high-speed rail VIP logo displayed on smartphone screens through the UE Logo solution.

Three cutting-edge technologies: 5G-A high bandwidth and high-speed rail private network, AI-native core network, and wireless universal intelligent service processing units.

Five key service scenarios: Seamless support for live streaming, video conferencing, online gaming, AI calling, and AI office.

New Frameworks for Experience-Centric Operations

The forum also saw the release of two industry white papers:

UE Logo 2.0 White Paper: Co-published by China Mobile Research Institute and Huawei, this paper focuses on terminal-network-business synergy, intelligent analytics, scenario-based engagement, and precision marketing. It proposes an end-to-end service framework that connects user engagement with closed-loop marketing, creating a new paradigm of network awareness, service accessibility, and experience-centric operations.

Agentic Core White Paper: Released by GSMA Intelligence, the paper outlines an AI-native intelligent core network architecture. The framework unlocks four key monetization capabilities: superior user experiences, advanced services, network capability openness, and agent service assurance. It also supports the development of new agent-centric communications services and expands innovation opportunities.

Unveiling the "Connection Agent"

China Mobile Research Institute, Huawei, and GSMA Intelligence jointly introduced the Connection Agent and a "China Mobile Bixing Agent Platform" Intent Openness Gateway. Built on a scalable modular architecture, the gateway enables seamless interoperability among AI agents while providing dedicated network services for each connected agent, setting a new benchmark for intelligent connectivity.

The launch marks a transition from traditional rule-based service delivery to agentic service orchestration, paving the way for next-generation intelligent connectivity. The solution has already been deployed in selected regions across China to support the incubation of innovative services.

Driving Cross-Industry Collaboration

To further strengthen industry collaboration, the forum officially launched the Terminal-Network-Industry Collaboration Initiative, promoting coordinated development across technology, business, and ecosystem dimensions.

Technology: Accelerate terminal ecosystem adaptation and standards certification for broad interoperability.

Business: Focus on high-value application scenarios and explore diversified monetization models

Ecosystem: Bring together partners across vertical industries to build a collaborative community based on pooled resources, co-developed capabilities, and shared risks and rewards.

Looking ahead, industry stakeholders will continue advancing mobile AI collaboration technologies and strengthening the foundation for next-generation digital productivity. Together, they will drive the evolution of communications infrastructure into an intelligent platform for ubiquitous connectivity and cross-domain collaboration, opening new opportunities in the mobile AI era.

In terms of speed and power, the GAC EMPOW is powered by the Mega Wave 2.0TGDI engine, accelerating from 0 to 100 km/h in just 6.95 seconds — like a striker's lightning burst, bringing the excitement of the pitch to everyday driving. For precise control, the AION i60 comes standard with an electric power steering system, L2 driver assistance and full-speed adaptive cruise control, delivering effortless handling and midfield maestro-like command.

On range and reliability, the AION V features Magazine Battery 2.0 technology and a CLTC combined range of over 600 km, eliminating range anxiety. Its rigorously tested dependability ensures steady performance, just like a player running nonstop throughout the match.

For safety, the GAC S7 is equipped with 10 airbags and whole-vehicle torsional rigidity of 35,000 N•m/deg, mirroring a team's coordinated defense to provide 360° protection for all occupants. Meanwhile, the HYPTEC HT is equipped with Bosch's latest-generation Intelligent Integrated Brake System (IPB), inheriting the calm resilience of a core player under pressure to master complex road conditions and emergencies.

As the football festival reaches its climax, GAC invites you to share this passionate journey through automobiles. This summer of football, let the game reveal GAC's commitment to quality and unshakable confidence.

For further information about GAC, please visit: https://www.gacgroup.com/en or follow us on social.

Later-line NSCLC – Potential to Overcome Immunotherapy Resistance
In heavily pretreated later-line NSCLC, CS2009 demonstrated encouraging antitumor activity, with most patients experiencing sustained tumor shrinkage. Across all dose levels, the 6-month duration of response (DOR) rate reached 85.7%. In the second-/third-line combination cohort, CS2009 achieved an ORR of 66.7% and a DCR of 100.0%. In the 30 mg/kg monotherapy cohort, patients whose disease had progressed following prior immunotherapy (IO) plus platinum-based chemotherapy —— a setting with significant unmet medical need—achieved an ORR of 30.8% and a DCR of 84.6%.

"Cold Tumors" – Meaningful Activity in Immunotherapy-Refractory Settings
In "cold tumors" with limited immunotherapy responsiveness, CS2009 monotherapy produced a 25.0% ORR and 87.5% DCR in heavily pretreated proficient mismatch repair/microsatellite stable metastatic colorectal cancer (pMMR/MSS mCRC). A 66.7% ORR and 100.0% DCR were observed when CS2009 was combined with XELOX in first-line mCRC. The current efficacy readout remains immature due to the short follow‑up for most patients in these two CRC cohorts. Additional monotherapy activity was seen in soft tissue sarcoma (STS) and non‑clear cell renal cell carcinoma (nccRCC) (ORR 33.3% each), reinforcing CS2009's potential to remodel the tumor microenvironment.

Updated Safety Data – Favorable Profile Confirmed with Longer Follow-up
With extended follow-up since initial presentation at European Society for Medical Oncology (ESMO) Congress 2025, updated Phase I safety data further confirmed the well-tolerated profile of CS2009. Importantly, no excessive toxicities typically associated with CTLA-4/PD‑(L)1 combinations observed. Among heavily pretreated patients with advanced solid tumors, Grade ≥3 treatment‑related adverse events (TRAE) occurred in 24.6% of patients, immune‑related adverse events (irAE) in 12.7% , and TRAE possibly related to anti-VEGF in 5.1%. This favorable safety profile was consistently maintained across both monotherapy and chemotherapy combination cohorts in first-line NSCLC.

Next Step – Phase III Registrational MRCT Planned by Year-End
The ongoing global Phase I/II trial has enrolled nearly 300 patients across China and Australia, with U.S. Investigational New Drug (IND) clearance now obtained. CStone plans to initiate the first Phase III global multi‑regional registrational trial (MRCT) for CS2009 by the end of 2026.

SUZHOU, China, June 1, 2026 /PRNewswire/ -- CStone Pharmaceuticals ("CStone," HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, immunology, inflammation, and other key disease areas, today announced that multiple key clinical updates for its core asset CS2009 (a PD-1/VEGF/CTLA-4 trispecific antibody) were presented in two posters at the American Society of Clinical Oncology (ASCO) Annual Meeting, covering Phase I/II clinical data in first-line and later-line NSCLC and CRC patients, as well as mature Phase I data from longer follow-up in patients with advanced solid tumors.

Dr. Jason Yang, CEO, President of R&D, and Executive Director at CStone, commented, "As the clinical evidence continues to mature, CS2009 has advanced beyond early mechanistic validation and preliminary efficacy exploration to deliver a compelling proof of concept (POC). We are encouraged by its consistently favorable safety profile, both as a monotherapy and in combination with chemotherapy, alongside broad antitumor activity across multiple treatment settings. CS2009 has demonstrated promising potential to address key challenges in cancer immunotherapy, including overcoming immunotherapy resistance and extending clinical benefit to tumor types that have historically shown limited responsiveness to immunotherapy. Robust antitumor activity has been observed across multiple cohorts, including both first-line and later-line NSCLC, as well as first-line and later-line pMMR/MSS mCRC. These data further validate the strength of CS2009's triple-target synergistic mechanism and support its potential to serve as a next-generation immunotherapy backbone. Importantly, the findings provide a strong foundation for our planned global Phase III registrational MRCT and reinforce our confidence that CS2009 could ultimately offer transformative treatment options for patients with lung cancer, colorectal cancer, and a broad range of solid tumors."

Key Highlights of the Poster Presentations：

Non-Small Cell Lung Cancer (NSCLC)

In the ongoing Phase I/II study, CS2009 was evaluated as monotherapy or in combination with chemotherapy in advanced NSCLC patients without actionable oncogenic alterations. A total of 108 patients were enrolled across four groups:

(1) Group 1 (≥2L NSCLC monotherapy), n=57: CS2009 was dosed at 10–45 mg/kg, once every 3 weeks (Q3W);

(2) Group 2 (2/3L NSCLC combination therapy), n=9: CS2009 was dosed at 20 or 30 mg/kg, Q3W plus docetaxel;

(3) Group 3 (1L NSCLC monotherapy ), n=23: CS2009 was dosed at 20 or 30 mg/kg, Q3W;

(4) Group 4 (1L squamous NSCLC combination therapy), n=19: CS2009 was dosed at 20 or 30 mg/kg Q3W plus paclitaxel/carboplatin, followed by CS2009 maintenance therapy.

1. Baseline Patient Characteristics

In Group 1 (≥2L NSCLC monotherapy), 61.4% had received one prior line of therapy, 21.1% two lines, and 17.5% three or more lines. In Group 2 (2/3L NSCLC combination therapy), all patients had received one prior line of therapy.

2. Robust Efficacy*

(1) Group 3 (1L NSCLC monotherapy, PD-L1 high expression TPS ≥50%, n=16):

ORR was 81.3% (13/16) with a DCR of 100.0% (16/16); response rates were comparable in squamous (ORR: 87.5%, 7/8) and non-squamous (ORR: 75.0%, 6/8) histologies.

(2) Group 4 (1L squamous NSCLC combination therapy, PD-L1 negative or low expression TPS ≤5%, n=8):

• ORR was 75.0% (6/8) and DCR 100.0% (8/8); notably, the ORR in the PD-L1 TPS <1% subgroup reached 100.0% (4/4).

(3) Group 1 (≥2L NSCLC monotherapy, most IO pretreated, n=54):

• Across dose levels: Most patients showed sustained tumor shrinkage; median DOR was not reached, and the 6‑month DOR rate was 85.7%.
• At 30 mg/kg: ORR was 24.0% (6/25) and DCR 60.0% (15/25); median DOR was not reached, with a 6‑month DOR rate of 80.0%. For patients who had received only prior immunotherapy plus platinum-doublet chemotherapy (n=13), ORR rose to 30.8% (4/13) and DCR to 84.6% (11/13).

(4) Group 2 (2/3L NSCLC combination therapy, n=6):

• ORR was 66.7% (4/6), and DCR was 100% (6/6).

3. Favorable Safety and Tolerability

(1) Group 1 (≥2L NSCLC monotherapy): The incidence of Grade ≥3 TRAE, irAE, and TRAE possibly related to anti-VEGF therapy were 19.3%, 12.3%, and 5.3%, respectively;

(2) Group 2 (2/3L NSCLC combination therapy): The incidence of Grade ≥3 TRAE was 44.4%, with no Grade ≥3 irAE or TRAE possibly related to anti-VEGF therapy observed;

(3) Group 3 (1L NSCLC monotherapy): The incidence of Grade ≥3 TRAE was only 4.3%, with no TRAE possibly related to anti-VEGF therapy observed;

(4) Group 4 (1L squamous NSCLC combination therapy): The incidence of Grade ≥3 TRAE and irAE were 26.3% and 10.5%, with no TRAE possibly related to anti-VEGF therapy observed.

Metastatic Colorectal Cancer (mCRC)

1. Later-line mCRC Monotherapy Cohort: 14 heavily pretreated patients with mCRC, mostly pMMR/MSS, received CS2009 30 mg/kg monotherapy. Among efficacy-evaluable patients (n=8), ORR was 25.0% (2/8) and DCR was 87.5% (7/8).

2. 1L mCRC Combination Therapy Cohort: 14 treatment-naïve mCRC patients, mostly pMMR/MSS, received CS2009 30 mg/kg plus XELOX. Safety data showed Grade ≥3 TRAE in 14.3%, irAE in 7.1%, and TRAE possibly related to anti-VEGF in 14.3% (all grade 1–2, isolated events). In patients with at least one post-baseline tumor assessment (n=6), ORR reached 66.7% (4/6) and DCR was 100.0% (6/6).

Phase I Dose Escalation in Advanced Solid Tumors: Safety, Efficacy, and PK/PD Characteristics

1. Baseline Patient Characteristics

A total of 118 heavily pretreated patients with advanced solid tumors were enrolled in the dose-escalation phase across six dose levels (1–45 mg/kg). Among them, 50.8% had prior immunotherapy and 45.8% prior anti‑angiogenic therapy.

2. Favorable Safety and Tolerability

(1) Dose escalation of CS2009 has been completed, with no Dose-Limiting Toxicities (DLTs) observed and Maximum Tolerated Dose (MTD) not reached;

(2) The incidence of Grade ≥3 TRAE, irAE, and TRAE possibly related to anti-VEGF therapy were 24.6%, 12.7%, and 5.1%, respectively. The incidence of infusion-related reactions was 4.2%, all grade 1-2 and manageable.

3. Overall Phase I Efficacy as Expected; Meaningful Signal in "cold tumors"

(1) In the overall efficacy-evaluable population (n=104), ORR was 17.3% (18/104) and DCR was 70.2% (73/104); median DOR was not reached, and the 6‑month DOR rate was 77.4%. At 20 mg/kg and 30 mg/kg, ORRs were 13.3% (4/30) and 22.7% (10/44), respectively, with DCRs around 70%.

(2) In addition to CRC, CS2009 monotherapy has also demonstrated encouraging antitumor activity in later-line 'cold tumors' that are insensitive to PD-(L)1, such as STS and nccRCC:

• STS (n=12): ORR 33.3% (4/12), DCR 66.7% (8/12);
• nccRCC (n=6): ORR 33.3% (2/6), DCR 100.0% (6/6).

4. Excellent PK/PD Characteristics

(1) CS2009 demonstrated linear PK with a half-life of 6-9 days, supporting Q3W dosing. No significant accumulation was observed at Cycle 3. The incidence of anti-drug antibody (ADA) positivity was extremely low at only 0.7% (1/139).

(2) PD profile demonstrated saturated receptor occupancy and robust T-cell activation/proliferation confirming PD-1/CTLA-4 blockade and deep and sustained VEGFA neutralization.

• Receptor occupancy (RO) of PD-1/CTLA-4 on peripheral T cells reached saturation throughout the dosing interval at doses ≥20 mg/kg.
• On cycle 1 day 8, CS2009 induced notable, dose-dependent upregulation of Ki67 (proliferation due to PD-1 and CTLA-4 blockade) and ICOS (activation due to CTLA-4 blockade) expression on both CD4+ and CD8+ T cells, collectively demonstrating effective PD-1 and CTLA-4 inhibition by CS2009.
• Serum-free VEGFA reduced deeply and rapidly across all dose levels, and the effect sustained throughout dose intervals.

CStone will continue Phase II dose expansion in selected tumor types for dose optimization and to generate data as monotherapy or in combinations, supporting registrational trials in NSCLC, CRC and other indications. The first Phase III global MRCT is expected to be initiated by the end of 2026.

About CStone

CStone (HKEX: 2616), established in late 2015, is an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, immunology, inflammation, and other key disease areas. Dedicated to addressing patients' unmet medical needs in China and globally, the Company has made significant strides since its inception. To date, the Company has successfully launched 4 innovative drugs and secured approvals for 21 new drug applications covering 9 indications. The company's pipeline is balanced by 16 promising candidates, featuring antibody-drug conjugates (ADCs), multispecific antibodies, immunotherapies and precision medicines. CStone also prides itself on a management team with comprehensive experiences and capabilities that span the entire drug development spectrum, from preclinical and translational research to clinical development, drug manufacturing, business development, and commercialization.

For more information about CStone, please visit: www.cstonepharma.com.

Forward-looking statements

The forward-looking statements made in this article only relate to events or information as of the date when the statements are made in this article. Except as required by law, we undertake no obligation to update or publicly revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. All statements in this article are made on the date of publication of this article and may change due to future developments.

Disclaimer: only for communication and scientific use by medical and health professionals, it is not intended for promotional purposes.

MUNICH, June 24, 2026 /PRNewswire/ -- Sungrow, the globally leading PV inverter and energy storage system provider, released its S+ Energy Storage Multi-Scenario White Paper at Intersolar Europe 2026. The white paper introduces a new framework to address the industry's most pressing challenges: delivering energy storage solutions that truly meet the diverse and evolving demands of real-world applications.

Energy Storage Moves Beyond One-Size-Fits-All

As energy storage is deployed across more applications, scenario differences are becoming more fundamental. Use cases such as renewable energy bases, AI data centers, PV-storage-charging stations, zero-carbon industrial parks, and off-grid microgrids each require distinctly different system capabilities and value priorities.

Even within generation-side storage, the logic can vary significantly. Renewable energy integration often requires longer-duration shifting, while grid-forming applications demand fast response and enhanced stability support. Emerging applications such as green hydrogen production further depend on tight coordination among power generation, storage, and electrolyzers.

These differences are no longer only about capacity, power rating, or duration. They reflect different operating conditions, grid constraints, and value objectives. The White Paper states that the era of using one standardized product to serve all scenarios is coming to an end.

The industry has widely discussed "scenario + energy storage," yet many solutions still follow a product-led approach — applying standardized systems to diverse projects, or relying on on-site hardware assembly and temporary tuning. Such models may enable deployment, but often struggle to match real project requirements or deliver long-term value.

"S+": Scenario, Synergy, Sustain

Sungrow's answer is embodied in the name S+, standing for Scenario, Synergy, and Sustain: scenario-defined solutions, native system synergy, and sustained value delivery. The White Paper calls for a shift from "applying products to scenarios" to "defining solutions by scenarios." True scenario-based design does not imply building every system from scratch; rather, it relies on a robust and reusable technological foundation to quickly configure the best solutions for different scenarios.

This approach reflects three core shifts:

• Scenario defines the solution
  At the core of S+ is a simple principle: scenario defines solution. Instead of treating storage as a physical add-on, S+ starts by deeply understanding the value logic, operating constraints, and lifecycle objectives of each scenario, then defines the role of energy storage accordingly.

• Native synergy, not assembly
  S+ also emphasizes native synergy, rather than patchwork integration. As projects involve more devices, vendors, and control systems, coordination becomes harder. Sungrow aims to build synergy into the system from the beginning through full-chain design, unified logic, and integrated system architecture.

• Sustained value delivery, not one-time handover
  S+ focuses on sustained value. Energy storage projects must operate reliably, adapt to changing market rules, and continue creating value throughout their lifecycle. By integrating scenario-based operation strategies, lifecycle O&M, and global service capabilities, Sungrow helps customers turn energy storage from a delivered project into a long-term value-generating asset.

A Unified Foundation for Diverse Scenarios

At the heart of S+ is a set of cross-scenario, reusable foundational capabilities, built on what Sungrow calls the "S+ Dual-Engine Foundation":

• Product Engine: Built on broad categories, extensive product series and shared design principles, enabling solutions to be configured accurately and operate smoothly across different applications.
• Platform Engine: Connecting the full value chain, from scenario insight, configuration and simulation to R&D, lean manufacturing, testing, operation and maintenance.

In essence, Sungrow uses the certainty of its foundation to offset the uncertainty of scenarios.

This capability is underpinned by nearly 30 years of expertise in the industry, over 1,000 GW of global engineering experience, and full-chain in-house R&D across wind, PV, storage, EV charging, hydrogen, and AI data center applications.

"With every stage connected, Sungrow has formed a chain of capabilities: insight defines needs, configuration generates solutions, simulation validates feasibility, R&D realizes designs, manufacturing ensures consistency, testing safeguards quality, operation delivers returns, and maintenance secures performance," said Dr. Cai Zhuang, General Manager of the Product Business Center at Sungrow Energy Storage Business Unit.

With S+, Sungrow delivers not a single storage system, but sustainable value designed for the uncertain scenarios of today and tomorrow. The S+ Energy Storage Multi-Scenario White Paper is now available on the company's official website. Please click the link: https://official-overseas-www.sungrowpower.com/en/white-paper

Contact:
Sungrow
Scarlett Rong
rongtianjiao@sungrowpower.com 

• ZTE showcased solutions that enhanced token efficiency and minimized the cost-per-token through the deep synergy of various elements, including SuperPod, extremely cost-efficient inference, and AIDC with ultimate energy efficiency
• ZTE has launched the NewStart AIOS and positioned it as the "technological foundation in the AI era"
• Centered on AI-native capabilities, ZTE has driven the deep integration of AI with existing networks—through architecture upgrades and key scenario innovations—to build a next-gen communications network.

SHANGHAI, June 26, 2026 /PRNewswire/ -- ZTE Corporation (0763.HK / 000063.SZ), a global leading provider of integrated information and communication technology solutions, showcased the TCO-optimal AI factory, an AIOS-powered ecosystem spanning scenario-based applications and innovative terminals, and cutting-edge breakthroughs in AI-driven networks at MWC Shanghai 2026. Through the extreme synergy across computing, network, storage, energy, and software, as well as system-level architecture innovations, ZTE fully unlocked new momentum for token operations.

As AI agents become widespread, industry competition focus is shifting from computing power scale to token efficiency. Leveraging its end-to-end, full-stack AI capabilities, ZTE is forging a complete value chain spanning token production, services, and circulation—to enable operators, enterprises, and industry partners to unlock AI value at scale.

Building a TCO-Optimal AI Factory for More Efficient, Cost-Effective Token Production

Token efficiency is the core competitiveness in this era of inference. TCO-optimal AI factories are the key to boosting token efficiency and achieving "token freedom".

At MWC Shanghai 2026, ZTE showcased solutions that enhanced token efficiency and minimized the cost-per-token through the deep synergy of various elements, including SuperPod, extremely cost-efficient inference, and AIDC with ultimate energy efficiency.

Building on 41 years of accumulated expertise in the R&D and engineering of ultra-large-scale, complex systems, ZTE has launched its SuperPod solution. Leveraging multi-chip open collaboration design and the innovative Orthogonal Electrical eXchange (OEX) architecture, it enables plug-and-play deployment and rapid provisioning. A single rack supports 128 GPUs, with high scalability up to 16,000 GPUs, laying a foundation for high-efficiency computing in model training and inference.

Through the synergy of network, storage, and computing, as well as hardware and software, ZTE achieves extremely cost-efficient inference. With non-blocking network and Global Server Load Balancing (GSLB), ZTE's solution enables efficient coordination across computing clusters ranging from thousands to tens of thousands of GPUs, further boosting overall inference efficiency.

Moreover, ZTE has developed its AIDC solution with ultimate energy efficiency, which integrates 800V HVDC power supply, full-stack liquid cooling, and intelligent computing-electricity synergy, enabling highly efficient and low carbon operations.

From computing cluster construction and inference efficiency optimization to green operations, ZTE is steering AI factories from being compute-centric to efficiency-driven, delivering a more cost-efficient and sustainable token production system.

Developing an Innovative AIOS Technological Foundation for Smarter Token Scheduling and Closed-Loop Services

The AI factory addresses the challenge of low-cost token production, while AIOS plays a critical role in token scheduling, orchestration, and service-oriented output.

ZTE has launched the NewStart AIOS and positioned it as the "technological foundation in the AI era". Built on AIOS, Co-Claw—an enterprise-level agent platform—is fully integrated into ZTE terminals, extending AI services to production and daily life.

For enterprises, the focus is on enhancing office and R&D efficiency and enabling intelligent operations, to achieve self-evolving workflows and closed-loop decision-making.

For homes, ZTE has launched innovative terminals with different screen sizes which serve as entry points to a fully connected smart home. They can be household AI assistant, AI entertainment companion, and AI security guardian—always on, always active for an intelligent lifestyle.

For individuals, the company has introduced a new AI-native paradigm spanning AI phones, AI cloud PCs, AI smart displays, FreeScreen and more, enabling personalized recommendations, contextual responses, and immersive interactions across travel, life, and work. AI knows better and delivers enjoyable smart experiences anytime, anywhere.

Leveraging the AIOS technological foundation, Co-Claw agent platform, and a full lineup of AI devices, ZTE transforms tokens into schedulable, serviceable, and monetizable resources. This allows operators and enterprises to develop a closed–loop model for token-based services.

AI + Network, Co-Building a Future of Intelligent, Ubiquitous 6G Connectivity

6G is more than a generational leap in connectivity. It also serves as the critical infrastructure that enables efficient token circulation in the AI era.

As a key participant in global 6G research and standardization, ZTE centers around "AI+" and "SAGIN", speeding up the evolution of 6G from research to commercial use.

Regarding SAGIN, ZTE has launched industry-leading LEO satellite communication payload solutions compatible with diverse application scenarios of SAGIN for 5G-A and 6G, fostering the critical connectivity foundation for a smooth evolution from 5G-A to 6G.

As for AI-native communications, ZTE has demonstrated its GigaMIMO solution and the world's first 256 TR U6G prototype in the 6G Zone at this event. With GigaMIMO, a cornerstone technology for 6G, the solution leverages architecture innovation, computing synergy, and algorithmic breakthroughs to systematically overcome critical bottlenecks in future network capacity, coverage, and spectral efficiency, thus speeding up 6G deployment and industry evolution.

Centered on AI-native capabilities, ZTE has driven the deep integration of AI with existing networks—through architecture upgrades and key scenario innovations—to build a next-gen communications network.

The AIR MAX solution comprehensively upgrades the network architecture with AI at its core and delivers a three-tier capability system involving the AI-native infrastructure, autonomous operations, and monetization engine. Together, they empower operators in capability evolution, service transformation, operational shift, and ecosystem reshaping for the AI era.

The AI HI-NET solution delivers three key capabilities—AI-native, ultra-high-speed and lossless, and intrinsically secure, laying a solid network foundation for ubiquitous intelligent computing access, lossless wide-area connectivity, and the integration of computing, network, security, and service.

The 10G AI-Optical Network solution has been widely deployed across homes, campuses, small businesses, and other key scenarios, unlocking greater value of all-optical cities.

Meanwhile, ZTE continues to promote key scenario applications through innovations such as new calling with AI assistant, "first-class" mobile network services, ISAC for low-altitude economy, and highly autonomous networks. These efforts are made to build a more intelligent, efficient, and trustworthy connectivity foundation for the AI era.

From AI factory to AIOS, agent platform, and future networks, ZTE demonstrated an end-to-end capability system at MWC Shanghai 2026. The system covers token production, scheduling, and circulation, integrating computing, network, terminals, and agents to accelerate AI from technological breakthroughs to large-scale deployment.

The AI industry is accelerating into the inference era, where tokens have become a key measure of AI-driven value creation. Looking to the future, ZTE will work with industry partners to build AI infrastructure and ecosystems that are more efficient, inclusive, and sustainable. Together, we aim to bring AI to various industries, unlocking new growth momentum for the AI era.

MEDIA INQUIRIES:
ZTE Corporation
Communications
Email: ZTE.press.release@zte.com.cn 

SAN DIEGO, April 23, 2026 /PRNewswire/ -- Abbisko Therapeutics (HKEX: 02256) announced that the company presented six latest preclinical and translational research findings in poster sessions at the American Association for Cancer Research (AACR) Annual Meeting, held from April 17 to 22, 2026, in San Diego, USA.

The presentations span multiple key innovation areas, including the pan-KRAS inhibitor ABSK211, the 4^th generation EGFR inhibitor ABK-EGFR-1, the CDK4 selective inhibitor ABK-CDK4, the MTA-cooperative PRMT5 inhibitor ABSK131, as well as a ctDNA-based study investigating resistance mechanisms to the FGFR2/3 inhibitor ABSK061.

pan-KRAS Inhibitor ABSK211

ABSK211 is a potent, highly selective, and orally bioavailable small-molecule pan-KRAS inhibitor developed by Abbisko Therapeutics. It demonstrates broad inhibitory activity against multiple KRAS mutations, addressing significant unmet medical needs in KRAS-driven cancers. At AACR 2026, Abbisko presented preclinical data for both monotherapy and combination strategies of ABSK211.

Monotherapy: Broad and Potent Inhibition Across KRAS Mutations

KRAS mutations are highly prevalent across multiple cancers, including pancreatic (~90%), colorectal (~35%), and lung cancer (~25%). While several pan-KRAS inhibitors have entered clinical development, there remains a critical need for enhanced potency.

In preclinical studies, ABSK211 demonstrated:

• Robust in vitro activity: ABSK211 significantly reduced cell viability across multiple KRAS alterations (including G12, G13, Q61, and WT amplification) at sub-nanomolar to nanomolar concentrations. Meanwhile ABSK211 displayed marginal inhibition in KRAS wild-type cell line with normal copy.

• Strong in vivo efficacy: Oral administration induced deep tumor regression in multiple KRAS G12V xenograft models, with robust target engagement.

• Broad mutation coverage: Consistent and significant antitumor activity was observed in models harboring KRAS G12D/C/S and G13D mutations.

These findings support the clinical advancement of ABSK211, which is currently undergoing IND-enabling studies.

Poster Information

• Title: Preclinical characterization of ABSK211: A highly potent, orally bioavailable and selective pan-KRAS inhibitor with broad and robust activity in KRAS-driven tumors
• Time: April 22, 2026, 9:00 AM – 12:00 PM (PT)
• Location: Poster Section 13, Board #10
• Abstract #: 7090

Combination Therapy: Multi-Mechanistic Synergy Enhances Antitumor Activity

Combination therapy is widely considered a key strategy to improve treatment outcomes in KRAS-mutant cancers. ABSK211 demonstrated synergistic antitumor activity with multiple therapeutic agents:

• In vitro synergy: Significant anti-proliferative synergy with PRMT5 inhibitors across KRAS mutations; strong synergy observed with EGFR monoclonal antibodies and chemotherapy in KRAS G12D/G12V models.

• Enhanced in vivo efficacy: Combination regimens with PRMT5 inhibitors, cetuximab, immunotherapies, and chemotherapy showed superior tumor growth inhibition and improved durability compared to monotherapy.

These results demonstrate that ABSK211 can significantly enhance antitumor efficacy through multi-mechanistic synergy, supporting its further development in combination strategies.

Poster Information

• Title: ABSK211, a highly potent and orally available pan-KRAS inhibitor, demonstrates robust antitumor efficacy in combination with multiple agents
• Time: April 22, 2026, 9:00 AM – 12:00 PM (PT)
• Location: Poster Section 13, Board #3
• Abstract #: 7083

4^th Generation EGFR Inhibitor ABK-EGFR-1

ABK-EGFR-1 is a novel 4^th generation EGFR inhibitor developed by Abbisko Therapeutics, specifically designed to target the EGFR C797S resistance mutation. It combines high selectivity with central nervous system (CNS) penetration to address key clinical challenges following resistance to 3^rd generation EGFR TKIs.

Targeting C797S-Mediated Resistance

The EGFR C797S mutation is a clinically validated mechanism of resistance to third-generation EGFR TKIs, with an estimated 51,000–146,000 cases annually worldwide. Currently, no approved therapies specifically target this mutation, representing a significant unmet clinical need. Preclinical studies showed that ABK-EGFR-1:

• Exhibits high selectivity over wild-type EGFR and other kinases.

• Demonstrates significant in vivo antitumor activity in multiple EGFR C797S-driven xenograft models, effectively inhibiting tumor growth.

• Possesses excellent blood-brain barrier penetration and favorable drug-like properties.

These findings support further development of ABK-EGFR-1 as a next-generation targeted therapy for EGFR-resistant cancers, particularly for patients with brain metastases.

Poster Information

• Title: Discovery and characterization of ABK-EGFR-1, a 4^th generation EGFR C797S Inhibitor with excellent selectivity and brain penetration
• Time: April 21, 2026, 2:00 PM – 5:00 PM (PT)
• Location: Poster Section 53, Board #7
• Abstract #: LB350

CDK4 Selective Inhibitor ABK-CDK4

ABK-CDK4 is a highly selective, brain-penetrant small-molecule CDK4 inhibitor developed by Abbisko Therapeutics. It is designed to selectively target CDK4, reduce CDK6-related toxicity, and expand treatment potential for patients with brain metastases.

Differentiation Through Selectivity and CNS Penetration

1^st generation CDK4/6 inhibitors (e.g., palbociclib, ribociclib, and abemaciclib) have demonstrated clinical benefit in breast cancer, but CDK6 inhibition is associated with dose-limiting hematologic toxicities. In addition, 20–40% of breast cancer patients develop brain metastases, while current therapies have limited CNS exposure.

Preclinical studies showed that ABK-CDK4:

• High selectivity: Over 50-fold selectivity for CDK4 versus CDK6, potentially reducing CDK6-related toxicity.

• CNS penetration: Favorable CNS exposure (Kpuu > 0.5) and drug-like properties.

• Antitumor activity: Effective inhibition of Rb phosphorylation and tumor growth in HR+/HER2− breast cancer models

These results suggest that ABK-CDK4 may overcome key limitations of current CDK4/6 inhibitors and provide a differentiated therapeutic option.

Poster Information

• Title: Discovery of ABK-CDK4, a selective and brain-penetrant CDK4 inhibitor
• Time: April 20, 2026, 9:00 AM - 12:00 PM (PT)
• Location: Poster Section 20, Board #13
• Abstract #: 1905

MTA-cooperative PRMT5 inhibitor ABSK131

ABSK131 is a potent and selective small-molecule MTA-cooperative PRMT5 inhibitor developed by Abbisko Therapeutics, targeting MTAP-deleted tumors, and is currently in clinical development.

Broad Synergy Across Multiple Therapeutic Modalities

MTAP homozygous deletion occurs in approximately 10–15% of solid tumors and frequently co-exists with oncogenic drivers such as KRAS and EGFR. In addition, MTAP abnormities are associated with poor prognosis following standard-of-care therapies across multiple cancer types. Therefore, there remains a significant unmet need for novel and effective combination therapies centered on MTA-cooperative PRMT5 inhibitor for MTAP-deleted tumors, with the potential to enable precision patient stratification and deliver synergistic therapeutic benefits.

Preclinical studies demonstrated that ABSK131 exhibits strong synergistic activity with multiple therapies:

• KRAS inhibitors: Enhanced tumor growth inhibition in KRAS-mutant, MTAP-deleted models when combined with AMG 510 or ABSK141.

• EGFR inhibitors: Improved anti-proliferative and in vivo antitumor activity in EGFR-mutant, MTAP-deleted NSCLC models when combined with osimertinib.

• MAT2A inhibitors: Consistent synergistic effects across multiple tumor models when combined with IDE397.

• Chemotherapy: Synergistic activity observed both in vitro and in vivo when combined with carboplatin in NSCLC models.

These findings support ABSK131 as a potential backbone therapy for combination strategies in MTAP-deleted tumors.

Poster Information

• Title: Synergistic antitumor activity of the MTA-cooperative PRMT5 inhibitor ABSK131 in combination with multiple therapeutic agents in diverse cancer models
• Time: April 21, 2026, 9:00 AM - 12:00 PM (PT)
• Location: Poster Section 14, Board #23
• Abstract #: 4504

FGFR2/3 Inhibitor ABSK061

ABSK061 is a highly potent and selective small-molecule FGFR2/3 inhibitor developed by Abbisko Therapeutics. It has demonstrated encouraging efficacy and safety in Phase I studies and is currently being evaluated in a Phase II trial for gastric cancer.

ctDNA Analysis Reveals Resistance Mechanisms

Acquired resistance remains a major challenge limiting the long-term benefit of targeted therapies. Using ctDNA-based next-generation sequencing (NGS), Abbisko conducted longitudinal genomic analyses comparing baseline and progression samples to elucidate resistance mechanisms to ABSK061:

On-target resistance: Polyclonal acquired FGFR2 mutations in the FGFR2 kinase domain were commonly observed in gastric cancer and cholangiocarcinoma.

Off-target resistance: FGFR2-Atered NSCLC was prone to develop acquired alterations in genes involved in RTK/RAS pathways.

These findings provide important molecular insights into resistance mechanisms and inform the design of future combination and sequential treatment strategies.

Poster Information

• Title: Circulating tumor DNA (ctDNA)-based profiling of acquired resistance to the fibroblast growth factor receptor (FGFR)2/3 inhibitor lavengratinib(ABSK061) in patient(pt)s with advanced solid tumors
• Time: April 21, 2026, 9:00 AM - 12:00 PM (PT)
• Location: Poster Section 45, Board #14
• Abstract #: 5319

At AACR 2026, Abbisko Therapeutics showcased the latest preclinical and translational research advances across multiple pipeline programs, demonstrating its strong capabilities in drug discovery and development. As these programs continue to advance into clinical stages, the company is further strengthening its globally competitive R&D platform.

Looking ahead, Abbisko Therapeutics will continue to focus on addressing unmet medical needs and accelerating the translation of innovative discoveries into clinical applications, with the goal of delivering more first-in-class and best-in-class therapies to patients worldwide.

The issuer is solely responsible for the content of this announcement.

Within this evolving landscape, Malaysia has steadily emerged as a trusted destination for healthcare among Myanmar patients. Its strong reputation is built on a combination of clinical excellence, accessibility, and a patient experience that prioritises comfort and continuity of care. Supported by close geographical proximity and connectivity, Malaysia continues to be a natural choice for patients seeking reliable treatment abroad.

Recent data highlights strong momentum in Malaysia's appeal among health tourists from Myanmar, with health tourist revenue increasing by 83% year-on-year, alongside a 93% surge in volume. This significant growth reflects rising awareness and confidence among Myanmar patients in seeking treatment abroad, particularly in destinations that offer trusted clinical outcomes, seamless patient journeys, and a high standard of care.

This upward trajectory underscores Myanmar's growing importance as a source market and reflects increasing patient confidence in seeking treatment abroad, particularly in destinations that offer trusted, high-quality care.

In response, the Malaysia Healthcare Travel Council (MHTC) will bring Malaysia Healthcare Week Yangon 2026 to Myanmar from 13 to 17 May 2026 at ParkRoyal Yangon. Organised in collaboration with Asian Primal Synergy, the initiative is part of Malaysia's broader efforts under the Malaysia Year of Medical Tourism (MYMT) 2026 campaign, themed Healing Meets Hospitality, to strengthen regional healthcare collaboration and expand access to quality care.

In the lead-up to Malaysia Healthcare Week Yangon 2026, a series of targeted communications initiatives have been rolled out to build awareness and strengthen public confidence in Malaysia's healthcare offerings.

This includes a three-part talk show series aired on Myanmar's national television and Mandalay FM radio during prime-time slots:

• Episode 1: Malaysia as a Healthcare and Family Destination (aired 25 April 2026) introduced Malaysia as a holistic destination that combines quality medical care with family-friendly experiences.
• Episode 2: Malaysia – World-Class Hospitals (airing 2 May 2026) features insights from medical professionals, highlighting seven participating Malaysian hospitals and their clinical expertise.
• Episode 3: Malaysia – A Patient Experience (airing 9 May 2026) showcases compelling testimonials from patients who have sought treatment in Malaysia, alongside perspectives from Myanmar Airways International on specialised services and travel packages for healthcare travellers.

These initiatives are designed to provide authentic, relatable, and credible insights into Malaysia's healthcare ecosystem, reinforcing patient trust and strengthening Malaysia's positioning as a preferred destination for medical travel.

The event itself will bring together leading Malaysian hospitals and serve as a platform for patients, partners, and stakeholders in Myanmar to better understand Malaysia's healthcare offerings, explore treatment options, and engage directly with medical professionals. It will also facilitate stronger partnerships across the healthcare ecosystem, including referral networks, corporate stakeholders, and industry players.

Through these efforts, Malaysia Healthcare continues to deepen its engagement with regional markets, reinforcing its position not only as a destination for treatment but as a trusted long-term healthcare partner in line with the aspirations of MYMT 2026.

For media inquiries and further information, please contact:

Mohamad Shahizam Fauzi
Head, Communications
+603 8776 6168
shahizam.f@mhtc.org.my

Siti Hamidah Mohd Najib
Senior Executive, Communications
+603 8776 6168
hamidah.m@mhtc.org.my

About Malaysia Healthcare Travel Council

Malaysia Healthcare Travel Council (MHTC), established in 2009 under the purview of the Ministry of Health (MOH) Malaysia, is entrusted with developing and nurturing the "Malaysia Healthcare" brand. MHTC enhances, coordinates, and promotes Malaysia's healthcare travel industry by fostering industry collaborations and building valuable public-private partnerships both domestically and internationally. With 80 member hospitals nationwide, MHTC continues to elevate the healthcare travel ecosystem through strong branding, seamless patient experiences, and strategic market initiatives. In line with these efforts, MHTC is spearheading the Malaysia Year of Medical Tourism (MYMT) 2026, the nation's first dedicated year to celebrate and advance healthcare travel. MYMT 2026 serves as a milestone initiative to showcase Malaysia's world-class healthcare offerings, strengthen its position as the premier global healthcare destination, and highlight the industry's significant contribution to the national economy.

More information can be found at https://www.malaysiahealthcare.org. 

HONG KONG, July 1, 2026 /PRNewswire/ -- DL Holdings Group Limited (1709.HK) announced its annual results for the year ended 31 March 2026 on 30 June. During the period, the Group recorded a net profit of HK$367 million, representing a year-on-year increase of approximately 168%; revenue of approximately HK$324 million, up 71% year-on-year; and net assets of approximately HK$2.721 billion, up 187% year-on-year. Total assets reached HK$3.35 billion, up 160% year-on-year. At the same time, DL Holdings' dividend plan for this period surpasses HK$160 million, comprising: HK$20 million in cash, HK$61 million in equity interests of DL Tower in the form of RWA, HK$39 million in fixed-income RWA linked to the ONE Carmel residential construction, and 40 million bonus shares.

Alongside this marked improvement in performance, the Group continued to advance its business restructuring and strategic upgrade, focusing on the development of financial services, family office, and digital finance segments, while continuing to strengthen its asset allocation and investment capabilities, driving the Group toward a new stage of diversified, platform-based, and innovation-driven development.

The Group has now established four core business segments working in synergy: first, traditional family office and asset management (DL Family Office, DL Asset Management); second, traditional securities brokerage and investment banking (DL Securities); third, digital assets and RWA (DL Digital Finance); and fourth, digital AI family office and investment finance community (NeuralFin and ARTi). 

On the proprietary investment side, the Group allocates capital around four core long-term assets, namely the top-tier ONE Carmel real estate project in California, USA; digital currency and digital gold; DL Tower; and private equity, private credit, and secondary market funds. Underpinned by this business matrix and asset base, the Group achieved a twofold leap in both revenue and profit during the reporting period, laying a solid foundation for the next stage of platform-based, innovation-driven growth.

Performance Highlights and Financial Results

During the period, the Group's core businesses maintained steady growth, with revenue increasing from HK$190 million in the prior year to HK$324 million, driven primarily by its licensed financial services business and family office services business. Of this, revenue from licensed financial services was approximately HK$120 million, and revenue from family office services was approximately HK$57 million, both recording year-on-year growth and continuing to serve as the Group's core revenue sources. Meanwhile, the Group's gross profit rose to HK$268 million, up 93% year-on-year, underscoring the resilience of its businesses through economic cycles.

On profitability, the Group's net profit for the year was HK$367 million, a significant increase from the prior year, driven primarily by fair value gains on financial assets at fair value through profit or loss, fair value gains on associates, and fair value gains on investment properties. Supported by these gains, together with a reduction in finance costs and a decline in administrative expenses, the Group's profit performance improved substantially for the year, with overall profitability notably enhanced.

In terms of financial position, the Group held cash and cash equivalents of approximately HK$370 million at year-end, reflecting a sound liquidity position. At the same time, the Group's asset base expanded significantly, with total assets notably higher than the prior year, primarily reflecting growth in financial assets, fair value investments, and assets related to business expansion. This demonstrates that the Group, while consolidating its traditional financial businesses, is also continuing to strengthen its capital operations and investment capabilities.

Building a Digital Finance Ecosystem Through Technology and Innovation, Empowering a Broader Base of Investors

During the reporting period, the Group continued to deepen its top-level digital finance strategy. Building on its established track record in cryptocurrency mining and digital asset investment, the Group simultaneously extended into the AI computing infrastructure sector, achieving coordinated development between digital assets and intelligent computing power. It secured core resources in North American data centers, GPU inference, and the conversion of crypto mining facilities, while expanding its channels for accessing overseas power supply and site resources, building a complete industry loop spanning crypto computing power, AI inference, and digital financial services. The Group is actively positioning its AI computing infrastructure as a new growth trajectory, further solidifying its "compute plus finance" tech-driven profile, and delivering on the digital finance strategy previously outlined in annual report.

Beyond its overseas infrastructure deployment, the Group also made parallel progress in its proprietary fintech businesses. NeuralFin (突触科技), in which the Group has invested, launched a suite of intelligent tools including AI-generated short-video research summaries, an AI wealth advisor, and Capital Radar, with the platform's registered users surpassing 190,000. Rice Vault (米倉), the financial social app dedicated to the Chinese mainland market, has been rolled out across all channels on the App Store and major Android app stores, using a financial community as the vehicle to connect content discovery, AI-driven research, and asset trading into a single end-to-end pathway, making mass-market investment services more accessible. Less than two months after launch, the app's users had already surpassed 40,000.

As product capabilities have matured, ARTi, the institutional-grade AI investment research platform for professional investors in which DL Holdings has invested, also reached an important development milestone, securing a US$1.5 million Pre-Series A investment from C Capital in June 2026 at a pre-money valuation of US$30 million. The platform is built on a proprietary multi-agent AI architecture, with a uniquely developed framework of 9 AI analysts × 9 investment masters × 9-layer data architecture for cross-validation, effectively addressing the pain point of financial hallucination common to general-purpose large language models. With its core strengths in fully traceable data and accumulable investment logic, the platform delivers a one-stop suite of institutional services spanning AI investment advisory and automated investment decision-making. Building on this technology, ARTi is accelerating its horizontal expansion into the prediction markets space, aiming to deliver forward-looking investment research products that cover macroeconomic events, policy trends, and asset price movements, thereby further enriching its AI-powered data services matrix.

Taken together, the Group has built a complete digital finance ecosystem spanning overseas AI computing infrastructure, institutional-grade professional investment research through ARTi, mass-market social wealth services through NeuralFin, and compliant virtual asset trading. The Group will continue to advance financial AI innovation within a compliant framework, broadening its digital finance growth curve. Looking ahead, the Group will use robust compliance as its foundation to drive more efficient synergy across its ecosystem's business units in terms of data, products, and customers.

Committed to Long-Termism, Deepening Investment in Cross-Border High-End Real-World Assets

Beyond its digital finance initiatives in AI computing power, ARTi's institutional AI research, and NeuralFin's consumer wealth platform, the Group has simultaneously continued to build out its long-term, cross-border, high-end real-world asset holdings: ONE Carmel, an art-focused real estate project in California, USA, has officially entered Phase 4.0.

Around this project, the Group has further strengthened its overall positioning across global asset allocation, family lifestyle, and art and wellness. Spanning approximately 3.6 square kilometers, ONE Carmel blends European artistic traditions, Asian lifestyle aesthetics, and Silicon Valley's AI innovation ecosystem. In partnership with leading European art institutions, the project has introduced a co-created Art Residence concept and is developing the ONE Plus Longevity and Wellness Center, building an integrated, low-profile luxury community that brings together humanities, technology, and health. Anchored by a dedicated foundation that sustains its cultural ecosystem, the project is positioned not as conventional real estate, but as a legacy asset carrying the family's spirit forward.

ONE Carmel forms a deep synergy with the Group's digital finance businesses: AI investment research and wealth tools such as ARTi and NeuralFin can provide clients with research and analysis on global real-world assets, while the project's high-quality underlying real assets are also well suited to the Group's RWA tokenization and cross-border family office allocation businesses. This year's dividend already includes HK$40 million of fixed-income RWA linked to the ONE Carmel residential construction.

Looking to the future, DL Holdings stands at a pivotal juncture in its transformation from a "comprehensive traditional financial services provider" to a company "building a wealth ecosystem for the digital AI era."  This twofold leap in net profit and asset scale is the reward for strategic discipline; the launch of its dividend policy is a sincere return of trust to its shareholders. And the deep convergence of digital finance with real-world assets, together with the two-way empowerment between AI technology and family office services, sketches out a clear growth trajectory for the Group's next chapter.

Global Industry Leaders Convene, Charting a New Chapter for the Intelligent Era

Liu Ying, Executive Vice President of China Telecom, stated in her speech that China Telecom closely align with the high-quality joint construction of the Belt and Road Initiative, promoting the deep integration of mature domestic technological capabilities with global cloud and network resources, and steadily enhancing its international operational strength. Through continuous cultivation, China Telecom has built an AI Token international operation capability system, consolidating the foundation for expanding the global market and deepening ecosystem cooperation. Based on the new stage of the AI Token era, China Telecom is committed to leveraging Token operations as a bond to share the new global computing network, co-create a new paradigm of AI services, jointly govern the new cross-border compliance order, and collectively embrace the new value of the digital intelligence wave.

The issuer is solely responsible for the content of this announcement.

AI-driven transformation, upgrading the partner alliance to keep pace with the times

Junfeng Li (Wind), Vice President of Huawei, CEO of Global Public Sector BU, pointed out in his keynote speech that we are in a wave of transformation driven by AI. As the bedrock of sustainable human development, the education and healthcare sectors face a global imperative for intelligent transformation—a challenge that concurrently harbors immense opportunities.

He emphasized Huawei's commitment to pioneering optimal pathways for the intelligent transformation of education and healthcare, aiming to leverage AI and other frontier technologies to democratize access to high-quality education and optimize healthcare delivery globally. The launch of the "AHEAD" Program is a crucial step for Huawei to work with global partners to build an industry community for the future.

Partner Alliance 2.0 deepens global cooperation in six dimensions

Scaling from the 1.0 infrastructure to a more integrated global ecosystem, the Partner Alliance 2.0 optimizes six critical collaborative pillars: trend insight, empowerment, solution co-creation, marketing, opportunity sharing, and expansion, collectively driving superior value for partners and customers.

Robert Yang, Director of Partner Development Dept, Global Public Sector BU, Huawei, outlined the core roadmap for the alliance upgrade, highlighting Huawei's intent to mobilize the collective expertise of global partners. By fostering a collaborative framework, Huawei is positioned to bring forth more innovative, industry-specific solutions, thereby driving a quantum leap in the digital and intelligent transformation of education and healthcare sectors.

The success of this Global Education & Healthcare Partners China Convention stands as a testament to the collective commitment of Huawei and its partners to advancing these sectors. Looking ahead, Huawei will deepen strategic synergy with partners to explore high-value application scenarios, co-innovate on cutting-edge technologies, and navigate global challenges. Together, Huawei and partners are set to redefine the roadmap for the digital and intelligent transformation of education and healthcare on a global scale.

Leading the New Era: A Dual-Engine Transformation Foundation

The PV sector enters high-quality development, prompting TCL Solar's dual layout across wafers and modules underpinned by three pillars: dominant wafer position, full industrial chain synergy and high-value product lineup.

Upstream, it consolidates silicon wafer advantages to solidify industrial fundamentals; downstream, it expands into high-efficiency modules centered on self-owned BC tech and builds a complete in-house wafer-to-module production system, capable of mass producing both BC and TOPCon products.

Silicon-Core Strength: Six Product Series Reconstructing the Value System

Wafers form TCL Solar's core business foundation. Its six customized wafer product lines set new industry benchmarks via premium quality and differentiated positioning, covering all mainstream technologies and market demands ranging from extreme performance and overseas high-end markets to cost-effectiveness and low-carbon requirements.

Guided by efficiency, intelligence and value upgrading, the firm leverages semiconductor-grade production and AI smart manufacturing to deepen cross-chain cooperation, empowering its high-reliability module development and Tier 1 development path.

Proprietary BC Leadership: Three Advantages Building a Technological Moat

Proprietary BC technology is TCL Solar's core driver for module business upgrading. As an early BC developer and mass producer, the company owns complete core patent layout across cell design, production and encapsulation.

Its BC competitiveness lies in three unique strengths: fully autonomous core IP, customized high-quality silicon wafers optimizing cell performance, and end-to-end self-controlled production enabling cost control and stable bulk delivery. Supported by these merits, the brand secures global BC leading status and paves the way for Tier 1 module supplier qualification.

Industry First: TOPCon Multi-Segment White Paper Redefines High-Efficiency Standards

Co-launched with TÜV Rheinland, TCL Solar's pioneering multi-segment module technology white paper defines new efficiency criteria. Its matching T5 PRO product obtains authoritative certification with notable power generation improvements, and the technology is poised for rapid market penetration in the coming years.

Scenario-Driven Strategy: Full Matrix Delivery for Tier 1 Strength

To qualify as a Tier 1 supplier, TCL Solar develops four core product families based on BC and TOPCon routes, covering ground power station, offshore, desert, commercial and residential scenarios with internationally recognized certification.

• Flagship BC Module: Built on advanced C3 BC processes with optimized packaging for global large-scale power projects.
• Smart Triple-Protection BC Module: Integrated multi-functional design for anti-shading, fire prevention and anti-dust to fit complex environments.
• Premium Residential BC Modules: Compact all-black and oversized shingled variants focus on rooftop aesthetics and higher power output for villas and distributed PV.
• Scenario Customized Products: T5 Pro for C&I and utility projects; salt-resistant marine module, self-clean desert module and lightweight rooftop module for respective harsh application environments.

Value Leap: Full-Chain Strength Establishes a Tier 1 Benchmark

TCL Solar's upgrade to Tier 1 module maker results from long-term tech accumulation and full-chain integration.

Going forward, the company will keep upgrading BC and TOPCon technologies, boost industrial synergy and global layout to jointly advance low-carbon PV development alongside worldwide partners.

RWA.LTD stated that consumer goods RWA is not a single product, but a set of new infrastructure developed around consumption scenarios, the circulation of consumer rights, and brand interaction. Since CEO Fu, Rao Tony first proposed the concept of "Consumer Goods RWA" in late 2024, the team simultaneously prepared the RWA.LTD platform and completed Beta testing in September 2025. Following several months of iteration, the platform completed a comprehensive upgrade in mid-March 2026, marking RWA.LTD's formal transition from the proof-of-concept stage to the ecological development stage.

RWA.LTD Ecosystem

In this public announcement, RWA.LTD systematically disclosed its four major ecological sectors for the first time. First, RWA.LTD | Mall (Winpoint Mall) was officially launched during the Hong Kong Web3 Festival, providing consumers with diverse brand rights driven by RWA Coin; current offerings include the CDAA (Chartered Digital Asset Analyst) Course, Matrix E-commerce Services, and more. Second, RWA.LTD | Exchange was fully launched in mid-March 2026 as a primary issuance and secondary trading market for consumer goods tokens, with plans to list 100 types of consumer goods tokens within the year to provide bidirectional exposure for brands and users. Third, RWA.LTD | Fund plans to collaborate with established VC funds to focus on brand token ecosystem construction and explore new paths for the synergistic development of consumer brands and on-chain capital. Fourth, RWA.LTD | Bot (rwaclaw.ai, rwabot.ai) has completed domain layout and is currently under development; it will provide consumers with real-time AI price comparisons, intelligent recommendations, and automated ordering tools to enhance decision-making efficiency and consumer experience.

RWA.LTD believes that the traditional consumer market has long suffered from information asymmetry, price opacity, and inactive membership systems, while the combination of blockchain and AI provides a new consumption model. By standardizing, digitizing, and placing consumer rights on-chain, consumers are no longer just end-buyers but can become active participants in the consumption network; brands are no longer limited to one-time interactions with consumers but can build stable, sustainable consumer relationships through on-chain tools.

Consumer RWA Alliance

At the Hong Kong Web3 Festival, the Consumer RWA Alliance, spearheaded by RWA.LTD, was inaugurated. The alliance aims to unite consumer brands, channel platforms, technology service providers, ecological partners, and cross-regional resource providers to jointly promote the co-construction of standards, ecological synergy, and scenario implementation for consumer goods RWA. The alliance members attending the unveiling ceremony included Dr. and Professor Lawrence Yu, Founder and Chairman of the Asia Pacific Economic Leaders' Confederation; Dr. Wang Ping, President of the RWA Ecological International Federation and Chairman of the Asia Pacific M&A Fund; Dou Jun, Secretary General of the Hong Kong RWA Global Industry Alliance and Executive Secretary General of the Blockchain Professional Committee of the China Communications Industry Association (CCIA); Dr. Yu Jianing, Principal of Uweb Business School (Hong Kong) and Rotating Chairman of the Academic Committee of the Hong Kong Certified Digital Asset Analysts Association (HKCDAA); Dr. Jingle, Founder of Hong Kong Meta Strategy; Dr. Qiu Yueying, CEO of Winchain Technology; Tongjian Sun, CEO of INOVAI TECH K.K.; and Wen Hua, Director of the Australia & New Zealand Center of the Hong Kong RWA Global Industry Alliance, with RWA.LTD CEO Fu, Rao Tony serving as the Chairman. The establishment of the alliance marks an important step for consumer RWA moving from platform exploration to industry collaboration, signifying that the RWA narrative is extending from the relatively singular field of financial assets to the consumer industry which is more closely related to real life.

Industry insiders pointed out that the establishment of the Consumer RWA Alliance holds industry significance beyond platform business. On one hand, it helps break the market's inherent impression of RWA as being "over-financialized" and encourages the outside world to re-recognize the application value of RWA as digital infrastructure in real consumption scenarios. On the other hand, it provides a new organizational framework for the Asian consumer market, making cross-regional brand cooperation, mutual recognition of consumer rights, and on-chain circulation mechanisms more operational. RWA.LTD stated that it hopes to promote the formation of a more diverse, open, and sustainable RWA world through the alliance mechanism, making RWA not just a synonym for asset securitization, but also a key driver for consumer innovation and industrial upgrading.

Regarding compliance issues of market concern, RWA.LTD provided a brief explanation in this announcement. Consumer goods tokens do not fall within the definition of "virtual assets" under Section 53ZRA of the Anti-Money Laundering and Counter-Terrorist Financing Ordinance (AMLO), as they are neither payment tokens nor governance tokens. Even if there is overlap in certain characteristics, the relevant tokens can ultimately be defined as "Limited Purpose Digital Tokens" under Section 53ZR of the AMLO, which are explicitly excluded from the scope of "virtual asset" in the AMLO. Based on this, RWA.LTD does not fall within the regulatory scope of the Virtual Asset Trading Platform (VATP) licensing regime. Meanwhile, the U.S. SEC's previous No-Action Letter to the Fuse project, along with the definition of "Digital Tools" in the regulatory interpretation published on March 17, 2026, further supports the stance that consumer goods tokens are non-securities, non-commodities, and are not regulated under the virtual asset framework. RWA.LTD emphasized that the company consistently adheres to advancing product design and business development within a compliance framework and will continue to monitor regulatory dynamics in different jurisdictions.

The RWA.LTD team possesses a rich international background and overseas market experience, having long followed the development trends of the Web3 and RWA markets in Europe and the United States. The team observed early on that the Asian RWA market has long been concentrated on financial narratives with relatively monotonous scenarios, and platforms that truly integrate deeply with mass consumption and high-frequency lifestyle scenarios remain scarce. Consequently, the team began preparing the consumer goods RWA platform as early as 2024, hoping to take the lead in completing infrastructure, model verification, and resource integration before an industry consensus was formed.

RWA.LTD CEO Fu, Rao Tony pointed out that consumer goods RWA is currently one of the directions most likely to land and scale quickly. Compared to financial RWA, consumer goods RWA has a stronger efficient foundation in terms of compliance structure, user understanding, scenario adaptation, and promotion paths. Its core value lies in using blockchain technology to release liquidity that the consumer industry has long lacked, allowing consumer rights—which were originally fragmented, dormant, non-tradable, or difficult to circulate across regions—to achieve more efficient allocation and redistribution. Through this mechanism, the relationship between brands, platforms, and consumers will be redefined.

Fu, Rao Tony further stated that as the digitalization of the Asian consumer market continues to improve, the combination of consumer RWA and the real consumer industry is expected to release trillion-dollar economic potential in the future. For Hong Kong, this is not just an emerging Web3 track, but could become an important hub connecting international consumer networks with digital asset innovation. Hong Kong possesses unique advantages as an international financial center, an international trade center, and a highland for institutional innovation. If it can take the lead in forming scale synergy in the field of consumer RWA, it has the opportunity to occupy a leading position in the global wave of consumer asset digitalization.

In the future, RWA.LTD will continue to advance its layout around consumer goods RWA infrastructure construction, ecological cooperation expansion, alliance network improvement, and AI consumer tool research and development, exploring new on-chain paradigms for the consumer industry with more brands, institutions, and partners. As the Mall, Exchange, Fund, and Bot sectors gradually mature, RWA.LTD hopes to drive consumer RWA from concept to large-scale application, providing a more efficient, intelligent, and participatory new value network for the Asian and global consumer markets.

About RWA.LTD

RWA.LTD is positioned as the Asian consumer goods asset trading center, committed to enhancing consumption efficiency with AI, reconstructing consumer value distribution with Web3, and establishing cross-city and cross-country consumer alliance networks via tokens. The company focuses on the consumer goods RWA track, continuously promoting the digitalization of consumer rights, the circulation of consumer assets, and the synergy of the consumer ecosystem to explore the future consumption model of "Smarter Consumer".

A strategic synergy of style, innovation, and environmental respect to drive the evolution of international yachting

MONACO, May 21, 2026 (GLOBE NEWSWIRE) -- North Sails Apparel announces its role as the Official Technical Clothing Partner of the Yacht Club de Monaco (YCM), one of the leading institutions driving innovation and excellence in international yachting. This collaboration brings together two maritime icons defined by a shared pursuit of sporting excellence, technical innovation, and a deep-rooted commitment to ocean conservation.

A Shared Vision of Excellence

Yacht Club de Monaco stands as a prestigious reference in international yachting, an exclusive private institution where tradition meets the visionary leadership of its President, HSH Prince Albert II. Housed in its iconic, Lord Foster-designed Clubhouse at the heart of Port Hercule, the YCM is the definitive hub for the global maritime elite. With a legacy of excellence and a forward-looking approach to sustainability, the Club provides the ideal environment for North Sails Apparel to showcase its high-performance DNA.

At the heart of the partnership lies a shared vision: authentic performance, technical credibility, and a forward‑looking approach to the sport. Together with YCM, North Sails Apparel expands its footprint across the Mediterranean’s top sporting landscape, strengthening its role as the premium brand for sailors worldwide.

"Being a partner of Yacht Club de Monaco is a significant recognition of our positioning within the international sailing," says Cedric Georges, CEO of North Sails Apparel. "Standing alongside an institution that embodies tradition, excellence, and vision allows us to bring our technical credibility and modern, performance‑driven vision to a highly authoritative stage. This partnership is both symbolic and strategic, placing North Sails Apparel at the heart of a community that lives and breathes the sea."

“As part of our collective approach Monaco, Capital of Advanced Yachting, we are proud to partner with North Sails Apparel, a benchmark in the world of sailing, recognised for its technical expertise and long-standing commitment to performance,” says Bernard d’Alessandri, General Secretary and General Manager of the Yacht Club de Monaco. “Through our flagship initiatives, such as the Monaco Classic Week – La Belle Classe (8-11 September 2027), the Primo Cup-UBS Trophy (4-7 March 2027), the Monaco Energy Boat Challenge (8-11 July 2026) and the SEA Index^®, we bring to life the complementarity between maritime heritage, innovation and environmental responsibility. This partnership with North Sails Apparel strengthens this dynamic, with a shared ambition to support the sustainable evolution of our sport and the wider industry.”

A Synergy of Design and Presence

Central to this partnership is a natural integration of technical expertise and lifestyle. Moving beyond a traditional sponsorship, the collaboration focuses on product development, with North Sails Apparel designing dedicated collections for the Yacht Club de Monaco’s boutique and key events. Function‑led design defines the project. Each garment, from official uniforms to technical sportswear, balances protection, reliability, and comfort. Using advanced materials and responsible production processes, North Sails Apparel equips YCM staff and athletes shaped by the evolving expectations of the sailing world.

More than a technical partnership, this union represents a shared dedication to the future of yachting. The collaboration between North Sails Apparel and Yacht Club de Monaco marks a decisive convergence of heritage and technical evolution. It is a synergy where maritime tradition meets advanced engineering, designed for a community that values both prestige and performance. By aligning their shared expertise, both institutions are committed to equipping the next generation of sailors with the tools and the vision to navigate an evolving landscape, driven by a profound respect for the sea.

For more information:
Press Office LaPresse - ufficio.stampa@lapresse.it

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5689b893-cb72-4f3c-bcba-df82371a288d

The report evaluates leading cloud service providers worldwide based on their Ability to Execute and Completeness of Vision.

Building on its success in China, Huawei Cloud is extending its proven capabilities to customers around the world through flexible strategies tailored to diverse enterprise needs. Huawei Cloud's core strengths include:

• Software-hardware-chip synergy and vertical integration. Huawei Cloud combines deep vertical integration with system-level innovation to drive the evolution of next-generation AI infrastructure. Its high-speed UnifiedBus network enables unified resource pooling across CPUs, NPUs, memory, storage, and DPUs. Powered by UnifiedBus, the next-generation AI Cluster Service (AICS) supports cloud supernodes with thousands of NPUs, as well as ultra-large clusters scaling to hundreds of thousands of NPUs. The Elastic Memory Service (EMS) delivers cache hit rates of up to 95% for ultra-long-context inference. CCE Volcano provides topology-aware scheduling and distributed inference acceleration across AI container clusters, significantly improving the performance and efficiency of large-scale enterprise AI workloads.
• Comprehensive AI products and solutions. Huawei Cloud offers a complete AI portfolio spanning AI infrastructure, model training and inference via ModelArts, AI-ready data processing with AI DataLake, data governance through DataArts, and full-stack AI security. This comprehensive portfolio empowers enterprises to manage the entire AI lifecycle—from large-scale training to production-grade inference—while significantly reducing deployment and operational complexity and ensuring robust, end-to-end AI security. Huawei Cloud has also launched its Industry AI Foundry, designed to accelerate AI adoption across industries by fostering ecosystem partnerships and helping customers deploy AI to solve real-world challenges. To date, it has launched dedicated zones for smart healthcare, embodied AI, and more.
• Powerful hybrid cloud AI deployment capabilities. Guided by its Cloud + Data + AI strategy, Huawei Cloud Stack redefines hybrid cloud for the agentic era through its comprehensive portfolio, including HCF, HCS, and HCSD. Whether organizations are looking to accelerate cloud migration, modernize by fully embracing cloud-native architectures, or build industry clouds and national sovereign clouds, Huawei Cloud Stack can deliver the solution best suited to their needs.

Huawei Cloud's recognition as a Leader highlights both its technological leadership and its growing influence in the AI infrastructure market. Since the end of 2025, Huawei Cloud has rapidly integrated its business and R&D resources around an AI-first strategy, while continuing to invest heavily in AI infrastructure to build the foundation for AI innovation. By introducing a new generation of AI infrastructure offerings, including AICS, Agentic Memory Storage (AMS), and unified general-purpose and AI compute scheduling, Huawei Cloud has significantly strengthened its competitive edge in software-hardware-chip synergy. Combining this foundation with the ModelArts platform, the AgentArts enterprise AI agent platform, and the Industry AI Foundry, Huawei Cloud is accelerating AI adoption across key industries such as finance and healthcare, ushering in a new era of AI-powered industry transformation.

Source: Gartner®, Magic Quadrant™ for Cloud AI Infrastructure, 6 July 2026

Reprint Link: https://www.gartner.com/doc/reprints?id=1-2NO0RHUH&ct=260706&st=sb

Disclaimer:

Gartner does not endorse any company, vendor, product or service depicted in its publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner publications consist of the opinions of Gartner's business and technology insights organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this publication, including any warranties of merchantability or fitness for a particular purpose. This graphic was published by Gartner, Inc. as part of a larger research document and should be evaluated in the context of the entire document. The Gartner document is available upon request from Huawei Cloud.

GARTNER and MAGIC QUADRANT are trademarks of Gartner, Inc. and/or its affiliates.

The Strategic Cooperation Agreement was officially signed by Jared Jiang, General Manager of Financial Service Industry, Tencent Cloud Hong Kong and Macau, and Tang Bin, Deputy Chief Information Officer of CNCBI. The signing ceremony was witnessed by Carlos Hu, Vice President of Tencent Cloud, and Wendy Yuen, Head of Personal & Business Banking Group, CNCBI.

Headquartered in Hong Kong, CNCBI is a leading Chinese-funded bank providing comprehensive commercial and investment banking services. CNCBI is a wholly-owned subsidiary of China CITIC Bank Corporation Limited and a member of CITIC Group, one of China's largest state-owned conglomerates. The bank is actively driving its FinTech 2.0 digital transformation, which is anchored on three strategic pillars: "Shenzhen-Hong Kong Synergy, AI-Driven, Phantomization".

Under the new agreement, the two companies are forming a powerful strategic partnership, joining forces to empower each other and co-create highly efficient, intelligent, and secure financial services. Central to this collaboration is a shared commitment to providing customers with a safer banking environment. By combining advanced technical innovation with robust data privacy considerations, the partnership will focus on driving intelligent risk control capabilities, reinforcing trust and safety in regional digital banking.

Furthermore, both parties will explore the deployment of innovative artificial intelligence capabilities to unlock greater operational efficiency across the board. This AI-driven approach is aimed at optimizing productivity within internal bank operations as well as elevating customer-facing services, streamlining workflows to meet evolving market demands in a highly competitive landscape.

To build a sustainable digital ecosystem, the collaboration provides comprehensive, end-to-end support for the bank's FinTech 2.0 digital transformation. Both parties will focus on accelerating the development of a next-generation core banking architecture while actively exploring domestic and national technology stack alternatives for financial systems. This robust foundation ensures a smooth technological evolution, setting a new benchmark for stable, compliant, and locally optimized digital infrastructure in the cross-border banking sector.

Jared Jiang, General Manager of Financial Service Industry, Tencent Cloud Hong Kong and Macau, said, "Our strategic cooperation with CNCBI represents a landmark collaboration in Hong Kong and Macau's financial services sector. By combining Tencent Cloud's secure cloud infrastructure and intelligent capabilities with CNCBI's FinTech 2.0 vision, we are setting new benchmarks for digital transformation and cross‑border financial innovation. This partnership underscores Hong Kong and Macau's role as leading hubs for regional financial technology development and highlights Tencent Cloud's commitment to enabling secure, intelligent, and future‑ready financial services."

Tang Bin, Deputy Chief Information Officer of CNCBI, said, "This strategic partnership marks a major milestone in our FinTech 2.0 journey, uniquely aligning with our Shenzhen‑Hong Kong Synergy strategy to create a flagship showcase for cross‑border financial technology. By establishing a strategic framework that strengthens our core infrastructure, operational efficiency, and security capabilities, we are building a progressive relationship that enables us to elevate customer experiences across Hong Kong, Macau, and the wider cross‑border banking sector."

About Tencent Cloud:

Tencent Cloud, one of the world's leading cloud companies, is committed to creating innovative solutions to resolve real-world issues and enabling digital transformation for smart industries. Through our extensive global infrastructure, Tencent Cloud provides businesses across the globe with stable and secure industry-leading cloud products and services, leveraging technological advancements such as cloud computing, Big Data analytics, AI, IoT, and network security. It is our constant mission to meet the needs of industries across the board, including the fields of gaming, media and entertainment, finance, healthcare, property, retail, travel, and transportation.

About China CITIC Bank International Limited

China CITIC Bank International is a Hong Kong-based full-service commercial bank that offers a broad spectrum of financial services spanning wealth management, personal banking, wholesale banking as well as global markets and treasury solutions. We aspire to grow into an outstanding bank that possesses professional capabilities to succeed with our customers, staff and community.

Following its success in setting an industry benchmark in 2025, this year's exhibition will further deepen strategic cooperation. With World Expo of Packaging Industry-Southeast Asia at its core, the event will synergize with the Paper Chain Expo, Pack Plus and Bakery ASEAN. Spanning an exhibition area of over 22,000 square meters, it will create an international trade platform covering the entire industrial chain—from raw materials and equipment manufacturing to packaging processing and terminal applications—injecting strong momentum into the collaborative growth of Chinese and Southeast Asian industries.

As the largest economy in Southeast Asia, Indonesia is rapidly becoming a vital hub for regional manufacturing and foreign investment. In recent years, the rapid development of sectors such as e-commerce, food delivery, food and beverage, and pharmaceuticals has continuously driven the demand for paper packaging, eco-friendly packaging, and smart packaging. With a market reaching over 600 million people in ASEAN, Indonesia holds a significant position in the regional and international packaging industry.

World Expo of Packaging Industry-Southeast Asia 2026 will continue to cultivate the Indonesian market, actively responding to the China-ASEAN industrial cooperation strategy. By once again partnering with industry organizations such as the Asosiasi Kotak Karton Gelombang Indonesia (AKKGI) and leveraging resources from packaging, papermaking, and printing associations across multiple countries, its international influence continues to rise. Notably, AKKGI will organize all its member units to attend this year and will host its 2026 Annual Convention and Gala Dinner concurrently with the exhibition, facilitating face-to-face exchanges with 500 industry elites and brand buyers.

Furthermore, the overall scale of the 2026 exhibition has been further upgraded, with a total display area exceeding 22,000 square meters. Leveraging the platform advantages of World Expo of Packaging Industry-Southeast Asia, the exhibition will highlight core segments of the packaging industry chain. Through synergy with the Paper Chain Expo and Pack Plus, it will provide a one-stop platform for display and exchange, covering paper raw materials and chemical agents, packaging and printing equipment, eco-friendly materials, smart manufacturing solutions, and terminal applications.

In terms of business matching, World Expo of Packaging Industry-Southeast Asia will continue to leverage its professional expertise. Through precise buyer invitations, one-on-one business matching, and the TAP (Targeted Attendee Program), it will focus on connecting core procurement decision-makers, brand owners, and distributors within the region. It is expected to attract over 25,000 high-quality target buyers, providing robust support for exhibitors to efficiently expand into Southeast Asian and international markets.

Focusing on industry hotspots, World Expo of Packaging Industry-Southeast Asia 2026 will host several high-level industry forums and themed activities that delve into critical topics such as the sustainable and smart future of the Southeast Asian packaging industry, green manufacturing and sustainable packaging, halal food packaging standardization and green supply chain synergy, smart packaging and digital factories, packaging for food delivery and ready-to-eat meals, innovative materials and molding technologies, as well as new breakthroughs in the industrial application of pulp molding and food paper containers. These sessions are designed to provide a high-value platform for information exchange and business expansion for both exhibitors and professional visitors, further strengthening the professional leadership of World Expo of Packaging Industry-Southeast Asia within the regional packaging industry.

In 2026, World Expo of Packaging Industry-Southeast Asia represents more than just an upgrade in scale and content; it is a commitment to the continuous cultivation and collaborative construction of the Southeast Asian packaging industry ecosystem.

We look forward to reuniting with global industry colleagues from August 27 to 29 at the Jakarta International Expo (JIEXPO), Indonesia.

Dr. Louis Liu, Founder & Group CEO of KUN, stated at the launch: "While the convergence of Web2 and Web3 defines the current era, we believe the embedded ecosystem synergy of AI and Web3 is the inevitable future of commerce. Our evolution is an intelligent reconstruction of commercial efficiency. By leveraging decades of vertical payment expertise, we provide enterprise clients with full-stack, end-to-end payment and financial solutions. Through digital orchestration and operations, we deliver secure, compliant, and high-velocity transaction safeguards to empower global business growth."

Money20/20 Roundtable: Compliance as the "Scaling Layer" for Institutional Adoption

At the "Bridging TradFi and DeFi" roundtable, Dr. Liu shared three key insights on the future of cross-border finance:

Asia as the Hub for Real-World Stablecoin Settlement: Asia has emerged as a critical hub for cross-border trade flows and stablecoin settlement, connecting high-growth emerging markets. Currently, 60% of the world's on-chain stablecoin trade volume is centered in Asia, making it a primary corridor for capital flows between Asia, LATAM, Africa, and the Middle East.

Compliance as the "Scaling Layer": The bottleneck for scaling digital payments is not technology or licensing, but the ability to embed jurisdictional compliance frameworks into business logic. Integrating AML and risk controls directly into the payment flow is the prerequisite for the explosion of global institutional applications.

Accelerating AI and Web3 Ecosystem Convergence: As AI agents increasingly enter commercial decision-making, payments are shifting from human-controlled to autonomous. Blockchain and stablecoins will serve as the default infrastructure for Agent-to-Agent (A2A) transactions.

Exhibition Interaction: From Platform Governance to Vertical Efficiency

At the main exhibition area, KUN demonstrated its dual-brand synergy through a new visual identity:

KUN: Positioned as the Trusted Vertical Digital Payments Platform for Real Economy, providing one-stop digital payments and scenario-based on-chain financial solutions.

YeeZ: A KUN Group brand specializing in 2B2C Global Corporate Card Issuance for global enterprises.

The "1-1-4-6" Strategic Blueprint: Driving Global Growth

KUN decoded its "1-1-4-6" strategy—an AI-powered blueprint designed for seamless asset mobility. The ecosystem integrates KUN Space™ (the digital payments & financial services platform) with KUN Nexus™ (the AI-orchestrated liquidity network). Driven by four core engines—KUN | Pay, KUN | Cards, KUN | Money, and KUN | Agent—the strategy empowers liquidity for six vertical sectors: Bulk Commodity, General Trade, B2B Cross-border E-Commerce, Service Trade, Web3 Ecosystems, and AI Applications.

Future Vision: The Era of "Driverless" Intelligent Payments

The launch highlighted KUN | Agent as the pioneer of the "driverless" era of intelligent global payments.

KUNClaw.AI: Orchestrates autonomous financial workflows to drive intelligent cost reduction and efficiency.

AI Agent Wallet: Features programmable KYC and authorization fences to ensure secure, compliant execution where "decision is payment".

Seamless Network, Borderless Payments.

KUN remains dedicated to serving as the engine for the real economy, providing secure, compliant, and efficient one-stop cross-border payment solutions in an uncertain global environment.

About KUN

KUN is an innovative financial infrastructure company centered on digital payments and embedded finance. Built on a globally distributed licensing framework and a robust compliance and risk-management system, KUN connects Asia with high-growth emerging markets across Africa, Latin America, and the Middle East.

Positioned as a trusted vertical digital payments platform for real economies, the company operates across four core pillars—Cross-Border Digital Payments, On-Chain Finance, Card Issuing, and AI Agentic Payments. By integrating artificial intelligence and blockchain technologies, KUN delivers secure, compliant, and efficient one-stop payment and transaction services for enterprise clients across industries including commodity trade, B2B cross-border e-commerce, service trade, Web3 ecosystems, and AI applications.

Through this integrated infrastructure, KUN serves as a growth engine enabling enterprises to expand globally with speed, trust, and financial connectivity.

Learn more about KUN → www.kun.global

Contact: KUN: brandmkt@kun.global  

• Green Logistics and Digitalization Construction: Both parties will actively explore sustainable transport solutions that comply with local regulations and authorities. By integrating Midea's business system with YANTIAN's terminal operating system, they will achieve real-time information sharing and seamless workflow connectivity, significantly enhancing cargo handling and transport efficiency.

• Port Operation Support: Addressing industry choke points such as peak-season logistical delays and capacity constraints, Hutchison Ports will open priority lanes for Midea during peak seasons. This will expedite the pick-up, return, and reloading of Midea's cargo, ensuring highly efficient dispatch operations and reinforcing the stability of Midea's supply chain.

• Port Extension Services and Multimodal Transportation: The partners will jointly develop rail freight solutions connecting inland Chinese ports to YANTIAN, alongside comprehensive terminal logistics support including container yards, warehousing, and other value-added services.

The issuer is solely responsible for the content of this announcement.

About Midea Group

Midea Group is a global technology group integrating seven business segments: Smart Home, Industrial Technologies, Building Technologies, KUKA, New Energy, Midea Healthcare, and ANNTO Logistics, fostering the parallel development of ToC and ToB businesses. Every year, it delivers satisfactory products and services to more than 500 million users worldwide, as well as key customers and strategic partners across various sectors. Currently, Midea operates more than 600 subsidiaries, 43 R&D centers and 65 major manufacturing bases worldwide, with business covering more than 200 countries and regions, and strives to become a global leader in smart homes and an enabler of smart manufacturing.

About Hutchison Ports

Hutchison Ports is the ports and related services division of CK Hutchison Holdings Limited. Hutchison Ports is the world's leading port investor, developer and operator with a network of port operations in 53 ports spanning 24 countries throughout Asia, the Middle East, Africa, Europe, the Americas and Australasia. Over the years, Hutchison Ports has expanded into other logistics and transportation-related businesses, including cruise ship terminals, distribution centres, rail services and ship repair facilities.

In 2025, Hutchison Ports handled a combined throughput of 90.1 million TEU.